TY - CHAP M1 - Book, Section TI - Pharmacogenomics A1 - Hibma, Jennifer E. A1 - Giacomini, Kathleen M. A2 - Katzung, Bertram G. A2 - Vanderah, Todd W. Y1 - 2021 N1 - T2 - Basic & Clinical Pharmacology, 15e AB - CASE STUDYA 35-year-old man with newly diagnosed human immunodeficiency virus (HIV) infection was prescribed an antiretroviral regimen that included the protease inhibitor atazanavir 300 mg to be taken by mouth once daily, along with ritonavir, a pharmacokinetic enhancer, and two nucleoside analog antiretroviral agents. Liver function and renal function were normal. After 1 year of treatment, the patient experienced visible yellow discoloration of the skin and eyes. Blood samples were drawn, and grade 4 hyperbilirubinemia was documented. When atazanavir was discontinued and the antiretroviral regimen was modified to include lopinavir, the plasma levels of bilirubin returned to the normal range, and skin and eye color were cleared. Could a UGT1A1*28 polymorphism have led to the adverse effects? SN - PB - McGraw-Hill CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1176969130 ER -